Noctura 400 is a monitored therapy - use of the mask is detected by sensors and recorded onto a chip inside the pod.
Once the patient returns their used mask, the collected usage data can be viewed and compared to changes in vision.
Noctura 400 is being used in clinic to treat patients with early stage DMO following the highly successful RENDER study where 96% of patients saw clinical improvement and stabilisation(2).
Across all stages of diabetic eye disease Noctura 400 has demonstrated clinical repair in 66% of patients, and no associated complications(2-6).
NICE have published a Medtech Innovation Briefing for Noctura 400 (6)
Noctura 400 has been used for people with
– Mild to moderate non-proliferative diabetic retinopathy (1,2)
– Early, untreated and progressive diabetic macular oedema (2-5)
– Moderate proliferative diabetic retinopathy (2)
After a period of treatment patients experience: